Updates in Therapeutics Conference - On Demand


Updates in Therapeutics Conference - On Demand Banner



Date & Location
Saturday, August 1, 2026, 7:00 AM - Thursday, December 31, 2026, 11:59 PM

Target Audience
Specialties - ALL
Professions - Pharmacist, Physician

Credits
AMA PRA Category 1 Credits™ (15.50 hours), Non-Physician Attendance (15.50 hours)

Overview

The inaugural Updates in Therapeutics Conference brings together pharmacists, physicians, and allied health professionals for an intensive two-day program examining emerging evidence, novel therapeutics, and evolving practice models across multiple disease states and clinical settings. Grounded in the latest clinical guidelines and research, this conference delivers actionable updates in cardiovascular-kidney-metabolic disease, infectious diseases, oncology, pulmonary medicine, pain and psychiatric disorders, and community health. Sessions integrate evidence-based pharmacotherapy with practical implementation strategies, case-based learning, and interprofessional perspectives to support optimal patient outcomes across the care continuum. This conference addresses critical knowledge gaps in rapidly evolving therapeutic areas including novel biologic agents, advanced cardiovascular-metabolic therapies, antimicrobial stewardship, checkpoint inhibitor toxicities, and emerging technologies reshaping clinical practice. Through expert-led presentations, interactive case discussions, and examination of contemporary guideline updates, participants will acquire evidence-based tools for medication optimization, toxicity recognition and management, and implementation of precision medicine approaches in diverse patient populations.


Objectives
Upon completion of this activity, learners should be able to:

  1. Apply evidence-based pharmacotherapy strategies incorporating recently approved agents and updated clinical guidelines across cardiovascular-kidney-metabolic disease, infectious diseases, oncology, pulmonary medicine, and psychiatric disorders
  2. Recognize and manage adverse effects and drug interactions associated with novel therapeutics including immune checkpoint inhibitors, oral targeted cancer agents, GLP-1 receptor agonists, and transplant-related immunosuppressive regimens.
  3. Implement systematic approaches to medication optimization in complex patient populations through application of guideline-directed medical therapy, risk stratification frameworks, and integration of pharmacogenomics and precision medicine principles.
  4. Evaluate the impact of social determinants of health, medication access policies, and emerging technologies (artificial intelligence, digital therapeutics, remote monitoring) on therapeutic decision-making, population health outcomes, and team-based models.
  5. Demonstrate collaborative practice strategies including appropriate specialist referral, interdisciplinary stewardship initiatives, and patient-centered communication to optimize therapeutic outcomes and advance team-based approaches in evolving healthcare delivery models.

Registration



REGISTRATION TYPE

REGISTRATION FEES

Physicians

$399

Pharmacists

$299


Accreditation

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this Enduring Material for a maximum of 15.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist: The California Board of Pharmacy accepts as continuing education for pharmacists' coursework which meets the standard of relevance to pharmacy practice and is accepted as continuing education by the Medical Board of California. 

Please note: ACPE credit is not available for this on demand activity. References to the claim credit process made during the recording apply to the live conference and do not apply to this activity. To claim AMA credit for this activity, please view the required content and then click the “Claim Credit” button within the Content tab. 


Additional Information

Cultural & Linguistic Competency and Implicit Bias: Continuing medical education (CME) providers are required by state Assembly Bills 1195 and 241, and the standards created by the California Medical Association (CMA), to include components that address cultural and linguistic competency and implicit bias in CME activities. The planners and presenters of this activity has been asked to provide meaningful consideration of these standards in the selection and presentation of content.  Additional information and resources are available on the
UC San Diego CPD website.


References

Obesity, GLP-1 Receptor Agonists, and Metabolic Health

  • Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;(360):1–8.

  • Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide-1 receptor agonists. Adv Ther. 2021;38:2821–2839.

  • Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide-1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc. 2023.

  • Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573–1583.

Pharmacogenomics and Precision Medicine

  • U.S. Food and Drug Administration. Table of Pharmacogenetic Associations.

  • Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC Guidelines and Gene-Drug Pairs.

  • Haidar CE, Petry N, Oxencis C, Douglas JS, Hoffman JM. ASHP statement on the pharmacist's role in clinical pharmacogenomics. Am J Health Syst Pharm. 2022;79(8):704–707.

  • Tamraz B, Shin J, Khanna R, et al. Clinical implementation of preemptive pharmacogenomics testing for personalized medicine at an academic medical center. J Am Med Inform Assoc. 2025;32(3):566–571.

Infectious Diseases, Antimicrobial Resistance, and Doxy-PEP

  • Infectious Diseases Society of America. 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. 2024.

  • Bachmann LH, Barbee LA, Chan P, et al. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention—United States, 2024. MMWR Recomm Rep. 2024;73(2):1–8.

  • Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388:1296–1306.

  • Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for treatment of complicated urinary tract infection. Clin Infect Dis. 2019;69(12):2045–2056.

Aminoglycoside Dosing and Therapeutic Drug Monitoring

  • Hodiamont CJ, van den Broek AK, de Vroom SL, et al. Clinical pharmacokinetics of gentamicin in various patient populations and consequences for optimal dosing for gram-negative infections: an updated review. Clin Pharmacokinet. 2022;61(8):1075–1094.

  • Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother. 2021;27(2):256–261.

  • Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacotherapy. 2018;38(12):1229–1238.

  • Bhavnani SM, Hammel JP, Onufrak NJ, et al. Evaluation of aminoglycoside dosing regimens adjusted for renal function and susceptibility criteria for Enterobacterales and Pseudomonas aeruginosa. Open Forum Infect Dis. 2025;12(12):ofaf426.

Health Equity and Pharmacoequity

  • FitzGerald C, Hurst S. Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics. 2017;18:19.

  • Essien UR, Dusetzina SB, Gellad WF. A policy prescription for reducing health disparities—achieving pharmacoequity. JAMA. 2021;326(18):1793–1794.

  • Abdul-Mutakabbir JC. Area-based deprivation indices and healthcare-associated infections: a narrative review of evidence. Curr Infect Dis Rep. 2025;27(1):20.

  • Abdul-Mutakabbir JC, Abdul-Mutakabbir R, Casey SJ. Utilizing an educational intervention to enhance influenza vaccine literacy and acceptance among minoritized adults in vulnerable Southern California communities. Infect Dis Rep. 2025;17(2):18.

Healthcare Systems, Patient Safety, and Artificial Intelligence

  • Angus DC, Khera R, Lieu T, et al. AI, health, and health care today and tomorrow: the JAMA Summit Report on Artificial Intelligence. JAMA. 2025;334(18):1650–1664.

  • U.S. Food and Drug Administration. Clinical Decision Support Software: Guidance for Industry and Food and Drug Administration Staff. 2026.

  • Bates DW, Levine DM, Salmasian H, et al. The safety of inpatient health care. N Engl J Med. 2023;388(2):142–153.

  • Poon EG, Lemak CH, Rojas JC, Guptill J, Classen D. Adoption of artificial intelligence in healthcare: survey of health system priorities, successes, and challenges. J Am Med Inform Assoc. 2025;32(7):1093–1100.

Dyslipidemia and Lipoprotein(a)

  • Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.

  • Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.

  • Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–1364.

  • Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Engl J Med. 2025;393(1):51–61.

  • Bhatia HS, Wandel S, Willeit P, et al. Independence of lipoprotein(a)- and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis. Circulation. 2025;151(4):312–321.

  • Greco A, Finocchiaro S, Spagnolo M, et al. Lipoprotein(a) as a pharmacological target: premises, promises, and prospects. Circulation. 2025;151(6):400–415.

Diabetes, Chronic Kidney Disease, and Heart Failure

  • American Diabetes Association Professional Practice Committee for Diabetes. Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).

  • Kidney Disease: Improving Global Outcomes (KDIGO). 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2024.

  • Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421.

  • Agarwal R, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025.

  • Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–127.

  • Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109–121.

California Pharmacy Law and Practice

  • California State Board of Pharmacy. 2026 Lawbook for Pharmacy.

  • California State Board of Pharmacy. Standard of Care Practice Model Policy Statement. Adopted November 6, 2025.

  • California State Board of Pharmacy. Statutory Changes in Law for 2026.

Vaccination, Vaccine Confidence, and Communication

  • Larson HJ, Gakidou E, Murray CJL. The vaccine-hesitant moment. N Engl J Med. 2022;387(1):58–65.

  • Labbé S, Bacon SL, Wu N, et al. Addressing vaccine hesitancy: a systematic review comparing the efficacy of motivational versus educational interventions on vaccination uptake. Transl Behav Med. 2025;15(1):ibae069.

  • Hill HA, Yankey D, Elam-Evans LD, et al. Decline in vaccination coverage by age 24 months and vaccination inequities among children born in 2020 and 2021—United States, 2021–2023. MMWR Morb Mortal Wkly Rep. 2024;73(38):844–853.

  • Murray E, Bienkeik K, del Aguila M, et al. Impact of pharmacy intervention on influenza vaccination acceptance: a systematic review and meta-analysis. Int J Clin Pharm. 2021;43(5):1163–1172.

Pulmonary Hypertension

  • Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.

  • Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension. Nat Rev Dis Primers. 2024;10:1.

  • Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325.

  • Humbert M, McLaughlin VV, Badesch DB, et al. Sotatercept in patients with pulmonary arterial hypertension at high risk for death. N Engl J Med. 2025;392(20):1987–2000.

Major Depressive Disorder and Emerging Treatments

  • U.S. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. 2022.

  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text rev. (DSM-5-TR). 2022.

  • Jagtiani A. Novel treatments of depression: bridging the gap in current therapeutic approaches. Explor Neurosci. 2024;3:272–286.

  • Zhou X, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18(11):pyv060.

Transplant Infectious Diseases and Antifungal Therapy

  • Lewis R, et al. Triazole antifungal drug interactions: a practical guide to management. J Antimicrob Chemother. 2024;79(6):1203–1217.

  • McCreary EK, et al. Therapeutic drug monitoring of triazole antifungals: insights from the SIDP TDM SIG. Pharmacotherapy. 2023;43(10):1043–1050.

  • Patterson TF, et al. Practice guidelines for the diagnosis and management of aspergillosis. Clin Infect Dis. 2016;63(4):433–442.

  • Pappas PG, et al. Clinical practice guideline for the management of candidiasis. Clin Infect Dis. 2016;62(4):e1–e50.

Severe Asthma and Biologic Therapy

  • Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2026.

  • Global Initiative for Asthma (GINA). Diagnosis and Management of Difficult-to-Treat and Severe Asthma: A GINA Guide for Health Professionals. 2026.

  • Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800–1809.

  • Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159:496–506.

Oncology, Oral Anticancer Therapy, and Immune-Related Adverse Events

  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Management of Immune Checkpoint Inhibitor-Related Toxicities. Version 1.2026.

  • Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126.

  • Herrmann J, Barac A, Carver J, et al. Immune checkpoint inhibitor-associated cardiovascular toxic effects: International Cardio-Oncology Society position statement. JAMA Oncol. 2026;12(1):90–99.

  • National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0.

  • American Society of Clinical Oncology. Guideline: prevention and management of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2020.

Cardiovascular Prevention, Coronary Disease, and Hypertension

  • Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2025;86(18):1567–1678.

  • Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation. 2025;151:e771–e862.

  • Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Circulation. 2023;148:e9–e119.

  • Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION). Lancet. 2022;400(10367):1927–1937.

  • Laffin LJ, et al. Lorundrostat in adults with uncontrolled hypertension. N Engl J Med. 2025;392(18):1813–1823.

  • Desai AS, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228–238.

MASLD/MASH and Emerging Metabolic Therapies

  • American Association for the Study of Liver Diseases. Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 Updates to AASLD Practice Guidance.

  • American Association for the Study of Liver Diseases. Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance.

  • Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509.

  • Loomba R, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310.

  • Huang DQ, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11(1):14.

Multimodal and Nonopioid Pain Management

  • Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95.

  • Finnerup NB. Nonnarcotic methods of pain management. N Engl J Med. 2019;380(25):2440–2448.

  • Wu CL, King AB, Geiger TM, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative joint consensus statement on perioperative opioid minimization in opioid-naïve patients. Anesth Analg. 2019;129(2):567–577.

  • Wiffen PJ, Xia J. Systematic review of topical diclofenac for the treatment of acute and chronic musculoskeletal pain. Curr Med Res Opin. 2020;36(4):637–650.

  • Bertoch T, D'Aunno D, McCoun J, et al. Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology. 2025;142(6):1085–1099.

  • Pérez C, et al. Pregabalin versus gabapentin in the treatment of neuropathic pain: a systematic review and meta-analysis. Front Pain Res. 2024.

Insomnia and Sleep Pharmacotherapy

  • Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. J Clin Sleep Med. 2017;13(2):307–349.

  • Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125–133.

  • Stefanou A, Lampropoulou P, Papageorgiou P, et al. The effect of dual orexin receptor antagonists on sleep: a systematic review and pairwise meta-analysis. Sleep Med. 2026;140:108792.

  • Maruani J, Reynaud E, Chambe J, et al. Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: a systematic review and meta-analysis. J Sleep Res. 2023;32(6):e13939.

LGBTQ+ Inclusive Healthcare

  • Caceres BA, Streed CG, Corliss HL, et al. Assessing and addressing cardiovascular health in LGBTQ adults: a scientific statement from the American Heart Association. Circulation. 2020;142(19):e321–e332.

  • Allen CL, Muschialli L, Nihlén Å, Coates A, Gonsalves LM. Barriers to sexual and reproductive health care faced by transgender and gender diverse people: a systematic review. Reprod Health. 2025;22(1):115.

  • American Society for Reproductive Medicine. Inclusive language and environment to welcome lesbian, gay, bisexual, transgender, queer, questioning, intersex, and asexual+ patients. Fertil Steril. 2024;121(6):954–960.

  • McKay T, Tran NM, Barbee H, Min JK. Association of affirming care with chronic disease and preventive care outcomes among lesbian, gay, bisexual, transgender, and queer older adults. Am J Prev Med. 2023;64(3):305–314.